Publications - Basic sciences

Here is a list of our most recent publications on the mechanisms of aging bone and osteoporosis. These papers report our results from in vitro experiments performed in mesenchymal stem cells and human osteoblasts as well as in vivo experiments in several mice and rats models.

2012
1. Interferon gamma inhibits adipogenesis in vitro and prevents marrow fat infiltration in oopherectomised mice. Vidal C, Bermeo S, Li W, Huang D, Kremer R, Duque, G. Stem Cells. 2012 (in press) PMID: 22331815 (Impact factor: 7.871)



2011
1. Lamin A/C deficiency is associated with fat infiltration of muscle and bone. Tong J, Li W, Vidal C, Yeo LS, Fatkin D, Duque G. Mech Ageing Dev. 2011 Dec; 132 (11-12):552-9. PMID: 21982926

2. Attenuated anabolic response to exercise in lamin A/C haploinsufficient mice. Duque G, Li W, Yeo LS, Vidal C, Fatkin D. Bone 2011 Sep;49(3):412-8. PMID: 21575749

3. Decreased bone formation and osteopenia in lamin a/c-deficient mice. Li W, Yeo LS, Vidal C, McCorquodale T, Herrmann M, Fatkin D, Duque G. PLoS One. 2011 Apr 25;6(4):e19313. PMID: 21547077

4.Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. Duque G, Huang DC, Dion N, Macoritto M, Rivas D, Li W, Yang XF, Li J, Lian J, Marino FT, Barralet J, Lascau V, Deschênes C, Ste-Marie LG, Kremer R. J Bone Miner Res. 2011 Jul;26(7):1472-83. doi: 10.1002/jbmr.350. PMID: 21308779

5. Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors. Duque G, Vidal C, Rivas D. Br J Pharmacol. 2011 Mar;162(5):1109-18. doi:10.1111/j.1476-5381.2010.01111.x. PMID:21077849



2009

1.Alendronate affects calcium dynamics in cardiomyocytes in vitro. Kemeny-Suss N, Kasneci A, Rivas D, Afilalo J, Komarova SV, Chalifour LE, Duque G. Vascul Pharmacol. 2009 Nov-Dec;51(5-6):350-8. Epub 2009 Oct 6.

2. Accelerated features of age-related bone loss in zmpste24 metalloproteinase-deficient mice. Rivas D, Li W, Akter R, Henderson JE, Duque G. J Gerontol A Biol Sci Med Sci. 2009 Oct;64(10):1015-24.

3. Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL/6J mice. Gasparrini M, Rivas D, Elbaz A, Duque G. Exp Gerontol. 2009 Sep;44(9):613-8.

4. Inhibition of Fatty Acid Biosynthesis Prevents Adipocyte Lipotoxicity on Human Osteoblasts In Vitro. Elbaz A, Wu X, Rivas D, Gimble JM, Duque G. J Cell Mol Med. 2009 Mar 27. [Epub ahead of print]

5. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Elbaz A, Rivas D, Duque G. Biogerontology. 2009 Mar 31.

6. Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis. Duque G, Huang DC, Macoritto M, Rivas D, Yang XF, Ste-Marie LG, Kremer R. Stem Cells. 2009 Mar;27(3):550-8.

7. Age-related bone loss in the LOU/c rat model of healthy ageing. Duque G, Rivas D, Li W, Li A, Henderson JE, Ferland G, Gaudreau P. Exp Gerontol. 2009 Mar;44(3):183-9. Epub 2008 Oct 21.

8. Effect of lamin A/C knockdown on osteoblast differentiation and function. Akter R, Rivas D, Geneau G, Drissi H, Duque G. J Bone Miner Res. 2009 Feb;24(2):283-93.

2008

1. Bone and fat connection in aging bone. Duque G. Curr Opin Rheumatol. 2008 Jul;20(4): 429-34.

2- Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome. Duque G, Troen BR. J Am Geriatr Soc. 2008 May;56(5):935-41.

2007

1. Inhibition of Protein Farnesylation Arrests Adipogenesis and Affects PPARgamma Expression and Activation in Differentiating Mesenchymal Stem Cells. Rivas D, Akter R, Duque G. PPAR Res. 2007;2007:81654.

2. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. Duque G, Rivas D. J Bone Miner Res. 2007 Oct;22(10):1603-11.

3. Age-related changes in lamin A/C expression in cardiomyocytes. Afilalo J, Sebag IA, Chalifour LE, Rivas D, Akter R, Sharma K, Duque G. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1451-6.

2006

1. Age-related changes in lamin A/C expression in the osteoarticular system: laminopathies as a potential new aging mechanism. Duque G, Rivas D. Mech Ageing Dev. 2006 Apr;127(4):378-83.

2005

1. Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Joseph C, Kenny AM, Taxel P, Lorenzo JA, Duque G, Kuchel GA. Mol Aspects Med. 2005 Jun;26(3):181-201.

2. Taking musculoskeletal aging out of the bench: do we finally understand frailty? Duque G. Mol Aspects Med. 2005 Jun;26(3):141-3.

3.1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R. Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E723-30.

2004

1. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Duque G, Macoritto M, Kremer R. Biogerontology. 2004;5(6):421-9.

2. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Duque G, El Abdaimi K, Henderson JE, Lomri A, Kremer R. Bone. 2004 Jul;35(1):57-64.

3. 1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma2). Duque G, Macoritto M, Kremer R. Exp Gerontol. 2004 Mar;39(3):333-8.

2003

1. Will reducing adopogenesis in bone increase bone mass?: PPARgamma2 as a key target in the treatment of age-related bone loss. Duque G. Drug News Perspect. 2003 Jul-Aug;16(6):341-6.

2002

1. Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation. Duque G, El Abdaimi K, Macoritto M, Miller MM, Kremer R. Biochem Biophys Res Commun. 2002 Dec 6;299(3):446-54.